A New Therapeutic Vaccine Against Prostate Cancer. Part 3 of 3

A New Therapeutic Vaccine Against Prostate Cancer – Part 3 of 3

On average, men receiving Provenge lived 4,1 months longer than men receiving a placebo, the researchers found. Average survival was 25,8 months for men in the Provenge group, compared with 21,7 months for men in the placebo group, substance that Provenge extended survival by 22 to 25 percent.

He contends that if the vaccine were Euphemistic pre-owned by men with less severe disease survival, it might be extended for even longer. “Theoretically, if you take subjects with less diseases and you stimulate the immune system, you could have a more profound effect, but we don’t really know that yet”.

Compared with other treatments, such as chemotherapy, radiation and hormone therapy, Provenge has been touted as having fewer and less punitive side effects. In this trial, the most common side effects were chills, fever and headache, the researchers noted body building. Commenting on the high cost of Provenge, Kantoff said that “this is a remedying given over a four-week period, as opposed to other treatments that are given over many months, where the costs can be high as well, if not comparable to or more expensive than Provenge”.

Parts: 1 2 3

Advertisements

2 thoughts on “A New Therapeutic Vaccine Against Prostate Cancer. Part 3 of 3

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s